ArticleInternational journal of hematology2022

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.

Lijie Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.